Mostra el registre parcial de l'element

dc.contributorUniversitat Ramon Llull. IQS
dc.contributor.authorSánchez García, David
dc.contributor.authorBorrós i Gómez, Salvador
dc.contributor.authorFornaguera Puigvert, Cristina
dc.contributor.authorMartínez Edo, Gabriel
dc.date.accessioned2021-07-25T16:17:25Z
dc.date.accessioned2023-07-13T05:45:44Z
dc.date.available2021-07-25T16:17:25Z
dc.date.available2023-07-13T05:45:44Z
dc.date.issued2020-11
dc.identifier.urihttp://hdl.handle.net/20.500.14342/1108
dc.description.abstractA pH-triggered mesoporous silica nanoparticle (MSN)-based nano-vehicle for the dual delivery of doxorubicin (DOX)/camptothecin-PEG (CPT-PEG) has been prepared. To enhance its selectivity, the nanoparticles were decorated with glycyrrhetinic acid (GA) to target HepG2 cells. The highly insoluble CPT was derivatized with a reductive-cleavable PEG chain to improve its loading within the MSN. The preparation of these particles consisted of four steps. First, CPT-PEG was loaded within the pores of the MSN. Then, dihydrazide polyethylene glycol chains were introduced onto the surface of an aldehyde-functionalized MSN by means of a hydrazone bond. Afterwards, DOX was covalently attached to the other end of the dihydrazide polyethylene glycol chains. Finally, the resulting nanoparticles were decorated with GA by formation of an imine bond between the amino group of DOX and a benzaldehyde-GA derivative. The system was stable at physiological conditions and the release of both drugs was negligible. However, at acidic pH, a burst release of DOX and a gradual release of CPT-PEG takes place. GA-decorated drug delivery systems (DDS) selectively internalizes into HepG2. In vitro tests demonstrated that this system shows a great cytotoxicity towards HepG2 cells. Furthermore, glutathione cleavage of CPT prodrug assures the formation of free CPT leading to a synergistic effect in combination with DOX.eng
dc.format.extent17 p.cat
dc.language.isoengcat
dc.publisherMDPIcat
dc.relation.ispartofPharmaceutics. Vol.12, n.11 (2020), 1048cat
dc.rightsAttribution 4.0 International
dc.rights© L'autor/a
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceRECERCAT (Dipòsit de la Recerca de Catalunya)
dc.subject.otherNanopartículescat
dc.subject.otherDoxorubicinacat
dc.subject.otherMedicamentscat
dc.subject.otherCàncercat
dc.subject.otherMesoporous silica nanoparticlescat
dc.subject.otherDual releasecat
dc.subject.otherDoxorubicincat
dc.subject.otherCamptothecincat
dc.subject.otherAnticancer drugscat
dc.subject.otherCombination therapycat
dc.subject.otherTargeting systemscat
dc.titleGlycyrrhetinic acid-functionalized mesoporous silica nanoparticles for the co-delivery of DOX/CPT-PEG for targeting HepG2 cellscat
dc.typeinfo:eu-repo/semantics/articlecat
dc.typeinfo:eu-repo/semantics/publishedVersioncat
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.termscapcat
dc.subject.udc539
dc.subject.udc616
dc.identifier.doihttps://doi.org/10.3390/pharmaceutics12111048cat
dc.relation.projectIDinfo:eu-repo/grantAgreement/MCIU/PN I+D/RTI2018-094734-B-C22cat
dc.relation.projectIDinfo:eu-repo/grantAgreement/SUR del DEC/SGR/2017-SGR-01559cat


Fitxers en aquest element

 

Aquest element apareix en la col·lecció o col·leccions següent(s)

Mostra el registre parcial de l'element

Attribution 4.0 International
Excepte que s'indiqui una altra cosa, la llicència de l'ítem es descriu com http://creativecommons.org/licenses/by/4.0/
Comparteix a TwitterComparteix a LinkedinComparteix a FacebookComparteix a TelegramComparteix a WhatsappImprimeix